Rule 3.19A.1

Appendix 3X

Initial Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available.	Information and
documents given to ASX become ASX's property and may be made public.	

Introduced 30/9/2001.

Name of entity Invex Therapeutics Ltd	
ABN 29 632 145 334	

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Thomas Duthy
Date of appointment	1 October 2020

Part 1 - Director's relevant interests in securities of which the director is the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

umber & class of securities		
Nil		

⁺ See chapter 19 for defined terms.

Part 2 – Director's relevant interests in securities of which the director is not the registered holder

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest.	Number & class of Securities
CIPA Investments Pty Ltd <cipa a="" c="" investments="">.</cipa>	106,923 ordinary shares
Dr Thomas Duthy is a Director and Shareholder of CIPA Investments Pty Ltd <cipa a="" c="" investments="">.</cipa>	

Part 3 - Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Consultancy Agreement
Nature of interest	800,000 unlisted options subject to shareholder approval at the Annual General Meeting.
	The options will be granted in accordance with the terms of the Incentive Option Plan and will include the following terms and conditions:
Name of registered holder	Issue price – nil Exercise price - \$1.30 Vesting – 50% upon completion of 12 months continuous service from date of issue and the balance upon completion of 24 months continuous service from the date of issue. Expiry date – 3 years from date of Issue.
Name of registered holder (if issued securities)	Not applicable
No. and class of securities to which interest relates	800,000 Unlisted options

Appendix 3X Page 2 11/3/2002

 $[\]boldsymbol{+}$ See chapter 19 for defined terms.